Stifel on Soleno Therapeutics Inc. (SLNO): 'we remain bullish and believe Vykat is well-positioned for significant/sustained growth'
Tweet Send to a Friend
Stifel analyst James Condulis reiterated a Buy rating and $118.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
